

DAFTAR PUSTAKA

- Al-Samkari, H. *et al.* (2021) 'Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19', *Annals of internal medicine*, 174(5), pp. 622–632. doi: 10.7326/M20-6739.
- Albani, F. *et al.* (2020) 'Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study', *EClinicalMedicine*, 27, p. 100562. doi: 10.1016/j.eclinm.2020.100562.
- Amirullah (2015) *Populasi dan Sampel*, Bayumedia Publishing Malang. doi: 10.1007/BF00353157.
- Aromataris, E. and Pearson, A. (2014) 'The systematic review: An overview', *American Journal of Nursing*, 114, pp. 53–58. doi: <https://doi.org/10.1097/01.NAJ.0000444496.24228.2c>.
- Barnes, G. D. *et al.* (2020) 'Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum', *Journal of Thrombosis and Thrombolysis*, 50(1), pp. 72–81. doi: 10.1007/s11239-020-02138-z.
- Baumann Kreuziger, L. *et al.* (2021) *COVID-19 and VTE-Anticoagulation - Hematology.org*, American Society of Hematology. Available at: <https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation> (Accessed: 18 November 2021).
- Berkman, S. A. and Tapson, V. F. (2021) 'COVID-19 and Its Implications for Thrombosis and Anticoagulation', *Seminars in Respiratory and Critical Care Medicine*, 42(2), pp. 316–326. doi: 10.1055/s-0041-1722992.
- Bettany-Saltikov, J. (2012) *How to do a Systematic Literatur Review in Nursing: A Step-by-Step Guide*. New York: McGraw-Hill Education.
- Bounds, E. J. and Kok, S. J. (2021) 'D Dimer', *StatPearls*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK431064/> (Accessed: 9 August 2021).
- Brunton, L. L., Hilal-Dandan, R. and Knollman, B. C. (2018) *Goodman and Gillman's The Pharmacological Basis of Therapeutics*, Mc-Graw Hill Education. doi: 10.1017/CBO9781107415324.004.

- Buijsers, B. *et al.* (2020) 'Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients', *EBioMedicine*, 59. doi: 10.1016/j.ebiom.2020.102969.
- Burhan, E., Susanto, A. D., *et al.* (2020) 'Pedoman Tatalaksana COVID-19.
- Burhan, E., Isbaniah, F., *et al.* (2020) *Pneumonia COVID-19*.
- Di Castelnuovo, A. *et al.* (2021) 'Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study *', *Thrombosis and Haemostasis*. doi: 10.1055/a-1347-6070.
- Cui, S. *et al.* (2020) 'Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia', *J Thromb Haemost*, 18, pp. 1421–1424. doi: 10.1111/jth.14830.
- Djoerban, Z. *et al.* (2020) 'Rekomendasi IDI Pemberian Antikoagulan Profilaksis Pada Pasien COVID-19 yang Dirawat di Rumah Sakit'.
- Ganiswarna, S. G. *et al.* (2001) *Farmakologi dan Terapi FKUI, Gaya Baru, Jakarta*.
- Garcia, D. A. *et al.* (2012) 'Parenteral anticoagulants - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines', *Chest*, 141(2 SUPPL.), pp. e24S-e43S. doi: 10.1378/chest.11-2291.
- Gómez-Mesa, J. E. *et al.* (2021) 'Thrombosis and Coagulopathy in COVID-19', *Current Problems in Cardiology*. Elsevier, p. 100742. doi: 10.1016/j.cpcardiol.2020.100742.
- Hippensteel, J. A. *et al.* (2020) 'Heparin as a therapy for COVID-19: Current evidence and future possibilities', *American Journal of Physiology - Lung Cellular and Molecular Physiology*, 319(2), pp. L211–L217. doi: 10.1152/AJPLUNG.00199.2020.
- Ho, F. K. *et al.* (2020) 'Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants', *PLoS ONE*, 15(11 November), p. e0241824. doi: 10.1371/journal.pone.0241824.
- Iba, T. *et al.* (2020) 'Coagulopathy in COVID-19', *Journal of Thrombosis and Haemostasis*, 18(9), pp. 2103–2109. doi: 10.1111/jth.14975.
- Ionescu, F. *et al.* (2020) 'Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort', *TH Open*,

04(03), pp. e263–e270. doi: 10.1055/S-0040-1716721.

- Ionescu, F. *et al.* (2021) ‘Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis’, *European Journal of Haematology*, 106(2), pp. 165–174. doi: 10.1111/ejh.13533.
- Joly, B. S., Siguret, V. and Veyradier, A. (2020) *Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19, Intensive Care Medicine*. Springer. doi: 10.1007/s00134-020-06088-1.
- Kamel, A. M. *et al.* (2021) ‘Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies’, *Reviews in Medical Virology*, 31(3). doi: 10.1002/rmv.2180.
- Katzung, B. G. (2018) *Basic & Clinical Pharmacology*. 14th edn. McGraw-Hill Education.
- Keputusan Menteri Kesehatan Republik Indonesia (2021) *Keputusan menteri kesehatan republik indonesia nomor hk.01.07/menkes/5671/2021 tentang manajemen klinis tata laksana*.
- Kordzadeh-Kermani, E., Khalili, H. and Karimzadeh, I. (2020) ‘Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19)’. doi: 10.2217/fmb-2020-0110.
- Lazaridis, D. *et al.* (2021) ‘The Impact of Anticoagulation on COVID-19 (SARS CoV-2) Patient Outcomes: A Systematic Review’, *Journal of Pharmacy Practice*. doi: 10.1177/08971900211015055.
- LB, W. and D., H. (2020) *Heparin*. StartPearls Publishing.
- Lee, S. G., Fralick, M. and Sholzberg, M. (2020) ‘Coagulopathy associated with COVID-19’, *CMAJ*. CMAJ, p. E583. doi: 10.1503/cmaj.200685.
- Li, Y. *et al.* (2020) ‘Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor’, *Pharmacological Research*. Academic Press, p. 104833. doi: 10.1016/j.phrs.2020.104833.
- Liu, H. *et al.* (2021) ‘Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention’, *Frontiers in Cardiovascular Medicine*, 0, p. 378. doi: 10.3389/FCVM.2020.599334.
- Moonla, C. *et al.* (2021) ‘Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis’, *Clinical and Applied Thrombosis/Hemostasis*, 27. doi:

10.1177/10760296211008999.

Mucha, S. R. *et al.* (2020) 'Coagulopathy in COVID-19: Posted april 24, 2020', *Cleveland Clinic Journal of Medicine*, 87(5), pp. 1–6. doi: 10.3949/CCJM.87A.CCC024.

National Institute of Health (2021) *COVID-19 Treatment Guidelines 2*. Available at: <https://www.covid19treatmentguidelines.nih.gov/> (Accessed: 17 November 2021).

Notoatmodjo, S. (2018) *Metodologi Penelitian Kesehatan*. 3rd edn. Jakarta: PT. Rineka Cipta.

Rentsch, C. T. *et al.* (2021) 'Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: Cohort study', *The BMJ*, 372. doi: 10.1136/bmj.n311.

Rosen, R. J. (2020) 'Thrombotic complications in critically ill patients with COVID 19', *Thrombosis research*, 191(January), p. 56. doi: 10.1016/j.thromres.2020.04.032.

Salah, H. M. and Mehta, J. L. (2021) 'Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19', *American Journal of Cardiology*, 142, pp. 158–159. doi: 10.1016/j.amjcard.2020.12.073.

Saydam, O. *et al.* (2019) 'Preoperative Low-Molecular-Weight Heparin Prophylaxis Associated with Increased Heparin Resistance Frequency in On-Pump Coronary Artery Bypass Graft Surgery'. doi: 10.1155/2019/4310407.

Shen, L. *et al.* (2021) 'The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19', *Cardiovascular Drugs and Therapy*. doi: 10.1007/s10557-020-07133-3.

Sherwood, L. (2018) *Fisiologi Manusia Dari Sel ke Sistem*.

Tambunan, K. L. *et al.* (2019) 'Konsensus Penatalaksanaan Tromboemboli Vena (TEV)', pp. 1–9.

Tang, N., Li, D., *et al.* (2020a) 'Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.', *Journal of thrombosis and haemostasis: JTH*, 18(4), pp. 844–847. doi: 10.1111/jth.14768.

Tang, N., Li, D., *et al.* (2020b) 'Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia', *Journal*

- of Thrombosis and Haemostasis*, 18(4), pp. 844–847. doi: 10.1111/JTH.14768.
- Tang, N., Bai, H., *et al.* (2020) ‘Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.’, *Journal of thrombosis and haemostasis: JTH*, 18(5), pp. 1094–1099. doi: 10.1111/jth.14817.
- Thachil, J. *et al.* (2020) ‘ISTH interim guidance on recognition and management of coagulopathy in COVID-19’, *Journal of Thrombosis and Haemostasis*, 18(5), pp. 1023–1026. doi: 10.1111/jth.14810.
- Vajari, M. K. *et al.* (2021) ‘COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management’, *Cell Biology International*, pp. 1–19. doi: 10.1002/CBIN.11623.
- Vaughn, V. M. *et al.* (2021) ‘Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized with COVID-19’, *JAMA Network Open*, 4(6), p. 2111788. doi: 10.1001/jamanetworkopen.2021.11788.
- Vene, N. and Mavri, A. (2018) ‘An Overview of the Anticoagulant Drugs Used in Routine Clinical Practice’, *IntechOpen*, 32(July), pp. 137–144. doi: <http://dx.doi.org/10.5772/intechopen.76206>.
- Wijaya, I., Andhika, R. and Huang, I. (2020) ‘The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review’, *Clinical and Applied Thrombosis/Hemostasis*, 26. doi: 10.1177/1076029620960797.
- Willim, H. A., Hardigaloh, A. T. and Supit, A. I. (2020) ‘Koagulopati pada Coronavirus Disease -2019 (COVID-19)’, *Intisari Sains Medis*, 11(3), pp. 749–756. doi: 10.15562/ism.v11i3.766.
- World Health Organization (2021) ‘WHO Coronavirus (COVID-19) Dashboard. WHO Coronavirus (COVID-19) Dashboard’, *Who*, pp. 1–5. Available at: <https://covid19.who.int/> (Accessed: 17 September 2021).
- Yang, J. *et al.* (2020) ‘Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor’, *Nature Communications*, 11(1). doi: 10.1038/s41467-020-18319-6.